Evidence map›Paper›PMID 39439868›Full record

SynthesisFarmaceuticos comunitarios2024

[Selection of pharmacogenomic variants and methodology for their use in community pharmacy].

A Montero-Gómez, A Sánchez Pozo

Abstract readEnglish AbstractSystematic Review
In one paragraph

Synthesis in Farmaceuticos comunitarios, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A Montero-GómezFarmacéutica Comunitaria y Máster en Atención Farmacéutica. Granada. España.
A Sánchez PozoCatedrático de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Granada. España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recognize pharmacogenetics as a key tool in their pharmacological guidelines for pharmaceutical counseling. In this context, community pharmacies play a crucial role in addressing this healthcare need, which could lead to a significant improvement in patients' quality of life by preventing ineffective or contraindicated treatments.In this work, we conducted a systematic review of the available scientific evidence regarding druggene interactions relevant to community pharmacy. We identified the main genes and polymorphisms associated with treatment response and adverse effects in primary care. Finally, we propose a model for implementing pharmacogenetic services in community pharmacies.

Indexed as

Community Pharmacy ServicesPharmacogeneticsHumansPharmaciesPharmacogenomic VariantsPolymorphism, GeneticAdverse effectsCommunity pharmacyCytochrome P450Genetic polymorphismGenotypeHLAPharmacodynamicsPharmacogeneticsPharmacogenomicsPharmacokinetics

Identifiers

PMID39439868
PMCPMC11491914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.